The study of ALT-801 in non-alcoholic fatty liver disease

This extension study will enroll subjects who have completed 12 weeks of treatment in Study ALT-801-105. It is designed to allow for an additional 12 weeks of treatment in order to assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic overweight and obese subjects with non-alcoholic fatty liver disease (NAFLD).

The trial is designed to enroll male and female 18 Years to 65 Years and is being conducted in the Catalina Research Institute, Montclair, California, United States; Panax Clinical Research, Miami Lakes, Florida, United States.

The study start date is March 2022.

This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05292911.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

The study of ALT-801 in non-alcoholic fatty liver disease

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe